Title
Antiepileptic drug therapy and recommendations for withdrawal in patients with seizures and epilepsy due to neurocysticercosis
Date Issued
01 September 2016
Access level
metadata only access
Resource Type
review
Publisher(s)
Taylor and Francis Ltd
Abstract
Introduction: Neurocysticercosis (NCC) is a leading causes of secondary epilepsy worldwide. There is increasing evidence on the epileptogenic role of NCC, and the presence of edema, calcified scars, gliosis and hippocampal sclerosis support this phenomenon. Areas covered: We summarized principles of antiepileptic drug (AED) therapy as well as risk factors associated with seizure recurrence after AED withdrawal in patients with NCC. Expert commentary: First-line AED monotherapy is effective as a standard approach to control seizures in most NCC patients. Risks and benefits of AED withdrawal have not been systematically studied, and this decision must be individualized. However, a seizure-free period of at least two years seem prudent before attempting withdrawal. Risk factors for seizure recurrence after AED withdrawal include a history of status epilepticus, poor seizure control during treatment, neuroimaging evidence of perilesional gliosis, hippocampal sclerosis and calcified lesions, as well as persistence of paroxysmal activity in the EEG.
Start page
1079
End page
1085
Volume
16
Issue
9
Language
English
OCDE Knowledge area
Parasitología
Neurología clínica
Subjects
Scopus EID
2-s2.0-84983089088
PubMed ID
Source
Expert Review of Neurotherapeutics
ISSN of the container
14737175
Sponsor(s)
National Institute of Allergy and Infectious Diseases R01AI116456
Fogarty International Center D43TW001140
Sources of information:
Directorio de Producción Científica
Scopus